Skip to Content
Merck
  • A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.

A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.

Nature communications (2018-02-02)
Guermarie Velazquez-Torres, Einav Shoshan, Cristina Ivan, Li Huang, Enrique Fuentes-Mattei, Harrison Paret, Sun Jin Kim, Cristian Rodriguez-Aguayo, Victoria Xie, Denise Brooks, Steven J M Jones, A Gordon Robertson, George Calin, Gabriel Lopez-Berenstein, Anil Sood, Menashe Bar-Eli
ABSTRACT

Previously we have reported that metastatic melanoma cell lines and tumor specimens have reduced expression of ADAR1 and consequently are impaired in their ability to perform A-to-I microRNA (miRNA) editing. The effects of A-to-I miRNAs editing on melanoma growth and metastasis are yet to be determined. Here we report that miR-378a-3p is undergoing A-to-I editing only in the non-metastatic but not in metastatic melanoma cells. The function of the edited form is different from its wild-type counterpart. The edited form of miR-378a-3p preferentially binds to the 3'-UTR of the PARVA oncogene and inhibits its expression, thus preventing the progression of melanoma towards the malignant phenotype. Indeed, edited miR-378a-3p but not its WT form inhibits melanoma metastasis in vivo. These results further emphasize the role of RNA editing in melanoma progression.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-ADAR1 antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody